“…However, predicting drug responsiveness has been challenging due to variability between patients. Lambda Biologics’ patient-derived organoids address this issue by reflecting the unique characteristics of individual patients. These organoids allow for the evaluation of drug responsiveness and differences based on patient diversity, providing valuable insights into personalized treatment strategies.”
